Jiangsu Paddington Biotechnology Co., Ltd.

Similar suppliers you may like

Nanjing Yanqiao Technology Co., Ltd.

🇨🇳 China

2023

11-50 people

Manufacturer/Trading Company

High-tech enterprise

OEM manufacturer

ODM manufacturer

Own brand

Key market

Asia

Description

Nanjing Yanqiao Technology Co., Ltd., established in 2022, is a modern high-tech chemical enterprise based in Nanjing, China. The company specializes in the R&D, production, and sales of chemical reagents, biological reagents, and fine chemical products. Operating as both a manufacturer and trading company, Nanjing Yanqiao Technology offers ODM and OEM services. With 11 to 50 employees, the company focuses on a diverse product portfolio including enzymes, proteins, amino acids, carbohydrates, plant hormones, separation materials, culture media, buffers, pigments, and chemical additives. Key products include Glycidyl Methacrylate, PC-300 Liquid Biological Preservative, Lipopolysaccharides, and various enzymes like Trypsin and Laccase. These products find wide application in chemical plants, power plants, pharmaceutical plants, water treatment processes, and various industries such as construction, agriculture, printing and dyeing, and scientific research. The company holds a business license and trademark, emphasizing quality and customer satisfaction.

Triacontanol; 593-50-0; Triacontanol; Melissyl Alcohol; 1-Hydroxytriacontane; Triacon-10$280

Guanine; 73-40-5; 2-Amino-6-Hydroxypurine; 2-Aminohypoxanthine; Imidoxanthin$0.17

6-Ba; 1214-39-7; 6-Benzyl Aminopurine; N-Benzyl-Adenine; 6-Benzylaminopurine; N- (Phenylmethyl) -1h-Purin-6-Amine; Benzyl (purin-6-yl) Amine$0.16

High Quality Experimental Reagents; Brassinolide; 80483-89-2; 28-Homobrassinolide$0.17

Labrafil M 1944 CS; Oleoyl Polyoxyl-6 Glycerides; Factory Price; Experimental Reagents$0.16

S-I-L-a-N-E Coupling Agent Kh590; Trimethoxytrimethoxysilane; 4420-74-0; Factory Price; Experimental Reagents$0.2

Trans-Ferulic Acid; 537-98-4; Trans-4-Hydroxy-3-Methoxycinnamic Acid$0.11

Biuret; 108-19-0; Allophamic Acid Amide; Carbamylurea; Imidodicarbonic Diamide; Biuret$0.17

Imidazole; 288-32-4; Glyoxaline; Iminazole; 1, 3-Diaza-2, 4-Cyclopentadiene; Pyrro[B]Monazole; Miazole$0.03

111-01-3; Cosbiol; Spinacane; Robane; Perhydrosqualene; Dodecahydrosqualene; Squalane$0.16

Sodium Thiosulfate Pentahydrate; 10102-17-7; Sodium Thiosulfate; Sodium Hyposulfite$0.01

Sodium Deoxycholate (Synthetic, insoluble in water) ; 302-95-4; Deoxycholic Acid Sodium Salt$0.5

Suzhou Womei Biology Co., Ltd.

🇨🇳 China

2010

201-300 people

Manufacturer/Trading Company/Service Company

Product customization

Patented technology

High-tech enterprise

ODM manufacturer

Shipments

Key customer

HANVET

Key market

🇻🇳 Vietnam

Description

Suzhou Womei Biology Co., Ltd. is a leading high-tech one-stop solution provider for the biopharmaceutical industry, headquartered in Suzhou, China. Established in 2010, the company operates as a manufacturer, trading company, and service provider specializing in upstream and downstream bioprocesses. With a workforce of over 200 employees and a strong R&D foundation rooted in the State Key Laboratory of Bioreactor Engineering, the company has established itself as a core supplier for antibodies, vaccines, and cell therapies. Their comprehensive product portfolio includes personalized serum-free culture media (CHO, BHK-21, 293, and SF9/SF21), advanced bioreactors ranging from laboratory scale to 15,000-litre ultra-large-scale systems, immune adjuvants, and high-purity biochemical reagents such as T7 RNA polymerase and deoxyribonuclease. Suzhou Womei Biology provides extensive contract manufacturing (OEM/ODM) and CDMO services, including formulation production, process optimization, and validation. The company maintains rigorous quality standards with ISO 9001, ISO 14001, and ISO 13485 certifications, alongside FDA DMF filings for its culture media. Serving a prestigious global clientele including Sinopharm, CanSinoBio, and WuXi AppTec, the company generates an annual output value between US$10 million and US$50 million, supporting the international expansion of innovative biopharmaceutical products.